REGULATORY
Dr Sakurai of PMDA Stresses Need for Japan’s Participation in PIC/S to Create Global Inspection System
Dr Shingou Sakurai, director of the Pharmaceuticals and Medical Devices Agency’s (PMDA) Office of GMP/QMS Inspection, discussed Japan’s participation in the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) and future changes in the Good Manufacturing Practice (GMP) at…
To read the full story
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





